Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(17%)
Results Posted
60%(3 trials)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
2
33%
Ph phase_3
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(5)

Detailed Status

Completed5
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 22 (33.3%)
Phase 32 (33.3%)

Trials by Status

completed583%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_3

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

NCT05145127
completedphase_3

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

NCT03938792
completedphase_1

Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia

NCT04878731
completedphase_2

PF-06741086 Long-term Treatment in Severe Hemophilia

NCT03363321
completedphase_2

PF-06741086 Multiple Dose Study in Severe Hemophilia

NCT02974855
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05145127Phase 3

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Recruiting
NCT03938792Phase 3

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Completed
NCT04878731Phase 1

Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia

Completed
NCT03363321Phase 2

PF-06741086 Long-term Treatment in Severe Hemophilia

Completed
NCT02974855Phase 2

PF-06741086 Multiple Dose Study in Severe Hemophilia

Completed
NCT02531815Phase 1

Dose Escalation Study of PF-06741086 In Healthy Subjects

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6